China-Italy biopharma joint lab launched in Shenzhen with the aim of advancing scientific and technological innovations.
The China-Italy Joint Laboratory of Pharmaceutical Biotechnology and Immunosafety has been inaugurated in Shenzhen, Guangdong Province, with the goal of advancing the international application of scientific and technological innovations in the biopharmaceutical sector.
This collaborative initiative was established by the Shenzhen Institutes of Advanced Technology (SIAT) under the Chinese Academy of Sciences, alongside Italy’s Institute of Biochemistry and Cell Biology and the Institute of Translational Pharmacology, both of which are part of the National Research Council (CNR) of Italy.
The laboratory will focus on two primary research areas: evaluating the immunotoxicity of natural and artificial substances and studying their pathogenic or toxic mechanisms, as well as developing immunomodulatory drugs and exploring strategies for disease prevention and immunotherapy, according to the laboratory’s director, Li Yang.
Xu Jianbin, vice president of SIAT, emphasized that the establishment of the joint laboratory has strengthened academic ties between China and Italy, offering a robust platform for collaborative research and innovation in the biomedical field.
Related Posts
